ACTIVEFINE Stock Overview
Produces and sells bulk drugs/active pharmaceutical ingredients (APIs) and various laboratory reagents in Bangladesh. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Active Fine Chemicals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳8.10 |
| 52 Week High | ৳21.50 |
| 52 Week Low | ৳7.50 |
| Beta | 0 |
| 1 Month Change | 2.53% |
| 3 Month Change | -5.81% |
| 1 Year Change | -47.40% |
| 3 Year Change | -68.24% |
| 5 Year Change | -43.75% |
| Change since IPO | -71.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACTIVEFINE | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | -3.6% | -3.1% | -0.8% |
| 1Y | -47.4% | -30.7% | -17.7% |
Return vs Industry: ACTIVEFINE underperformed the BD Pharmaceuticals industry which returned -30.7% over the past year.
Return vs Market: ACTIVEFINE underperformed the BD Market which returned -17.7% over the past year.
Price Volatility
| ACTIVEFINE volatility | |
|---|---|
| ACTIVEFINE Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BD Market | 7.1% |
| 10% least volatile stocks in BD Market | 2.8% |
Stable Share Price: ACTIVEFINE has not had significant price volatility in the past 3 months compared to the BD market.
Volatility Over Time: ACTIVEFINE's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | S. M. Rahman | www.afchem.com |
Active Fine Chemicals Limited produces and sells bulk drugs/active pharmaceutical ingredients (APIs) and various laboratory reagents in Bangladesh. The company’s APIs include azithromycin dihydrate, erythromycin ethyl succinate, and erythromycin stearate for macrolide-antibiotics; esomeprazole magnesium trihydrates and pellets for anti-ulcerant; fluconazoles for anti-fungal; atorvastatin and rosuvastatin calcium for lipid-lowering; cetirizine and fexofenadine hydrochlorides, desloratadines, and ebastine for anti-histamine; and ciprofloxacin hydrochloride for anti-bacterial therapeutics. It also offers cefixime trihydrates and cefuroxime axetil for cephalosporin-antibiotics; metformin hydrochloride, sitagliptin phosphate monohydrate, vildagliptin, linagliptin, gliclizide, and glimepiride for anti-diabetic; pregabalin for anti-epileptic; paracetamol for analgesic and antipyrotic; losartan potassium and amlodipine besylate for anti-hypertensive; calcium orotate for use in calcium-supplement; sofosbuvir for anti-hepatitis-C; etoricoxib and ketorolac tromethamine for NSAID; and ticagrelor and amlodipine besylate for anti-platelet therapeutic areas, as well as solvents and powder reagents.
Active Fine Chemicals Limited Fundamentals Summary
| ACTIVEFINE fundamental statistics | |
|---|---|
| Market cap | ৳1.94b |
| Earnings (TTM) | -৳4.54m |
| Revenue (TTM) | ৳1.35b |
0.0x
P/S Ratio0.0x
P/E RatioIs ACTIVEFINE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACTIVEFINE income statement (TTM) | |
|---|---|
| Revenue | ৳1.35b |
| Cost of Revenue | ৳1.02b |
| Gross Profit | ৳336.56m |
| Other Expenses | ৳341.10m |
| Earnings | -৳4.54m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ACTIVEFINE perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 20:30 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Active Fine Chemicals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|